Compare VYGR & BNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYGR | BNY |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.4M | 245.3M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | BNY |
|---|---|---|
| Price | $3.89 | $10.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 667.5K | 52.7K |
| Earning Date | 03-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,316,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.65 | $8.60 |
| 52 Week High | $5.78 | $10.80 |
| Indicator | VYGR | BNY |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 53.32 |
| Support Level | $3.86 | $10.10 |
| Resistance Level | $4.11 | $10.31 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 47.79 | 40.74 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.